Older Adults Using Prescribed Cannabis Report Well-Being Improvements, But Causal Claims Remain Unsupported

A UK registry study finds notable differences in who seeks medical cannabis after age 65 and how it is prescribed, offering the largest descriptive dataset for this population in the UK to date, but the uncontrolled observational design prevents any conclusions about whether cannabis-based products caused the reported improvements.

Why This Matters

Older adults carry a disproportionate burden of chronic pain and are increasingly interested in cannabis-based medicinal products, yet they have been systematically excluded from most clinical trials of cannabinoids. Clinicians face growing patient demand with almost no age-specific efficacy or safety data to guide prescribing decisions. This study, drawn from the largest UK cannabis patient registry, provides the first detailed look at how older adults in private-sector cannabis clinics differ from younger patients and what they report experiencing over time. That descriptive groundwork matters, even as the design falls well short of answering whether the treatments work.

Clinical Summary

Chronic pain management in older adults remains a significant clinical challenge, with many patients seeking alternatives to conventional analgesics. Researchers analyzing data from the T21 registry, a prospective observational patient registry operated across UK private-sector telemedicine cannabis clinics and published in Drugs & Aging in 2024, examined whether adults aged 65 and older differed from younger patients in demographics, indications, prescribing patterns, and self-reported well-being outcomes. The mechanistic rationale rests on the endocannabinoid system’s known involvement in pain modulation, sleep regulation, and mood, though translating that biology into demonstrated clinical benefit in older adults requires evidence this study design cannot provide.

Among 4,228 enrolled patients, 198 (4.7%) were aged 65 or older. Older patients were more likely to be female (52.5% versus 47.0%), to present with pain as their primary condition (76.3% versus 45.6%), and to have minimal prior daily cannabis use (20.2% versus 60.3%). They were prescribed fewer products on average and received more CBD-dominant oils and less THC-dominant flower. Over three months, statistically significant improvements were observed in quality of life, general health, mood, and sleep in both age groups (all p<0.001), though sleep gains were less pronounced in older adults. However, attrition was substantial, with roughly 50% of the older subgroup lost to follow-up by three months. Without randomization, blinding, or a control group, the authors acknowledge that improvements could reflect natural disease course, regression to the mean, placebo effects, or selective retention of responders, and they call for controlled trials before clinical recommendations can be made.

Dr. Caplan’s Take

This study does something genuinely useful by characterizing the older adults who actually show up seeking prescribed cannabis in the UK. The demographic and prescribing differences are striking and clinically informative: these are predominantly pain patients, mostly cannabis-naive, receiving lower-THC formulations. That descriptive portrait matters for clinical planning. But when a patient over 65 asks me whether medical cannabis will improve their quality of life or sleep, this study cannot support a confident yes. The improvements look encouraging on the surface, but without a control group and with half the older cohort dropping out, I cannot distinguish a real treatment effect from optimistic self-report, expectation bias, or the tendency for people who feel worse to simply stop participating.

In practice, I treat older adults with cannabis-based products cautiously and selectively, starting low and going slow, particularly with THC. I use validated outcome measures to track response individually rather than relying on population-level signals from uncontrolled registries. If a patient is not demonstrating measurable benefit within a reasonable timeframe, I reassess rather than assume the registry data justify continuation. We need proper controlled trials in this age group before we can move beyond careful empiricism.

Clinical Perspective

This study sits at an early, hypothesis-generating stage of the research arc for cannabinoid therapy in older adults. It confirms what smaller datasets have suggested: that older patients seeking cannabis differ substantially from younger cohorts in their clinical profiles and that prescribers already appear to adjust product selection accordingly, favoring CBD-dominant formulations and lower overall product counts. What it does not and cannot confirm is therapeutic efficacy. Clinicians should not cite these findings as evidence that cannabis-based products improve quality of life or sleep in geriatric populations. The within-group improvements, while statistically significant, carry the full weight of every confounder that uncontrolled observational designs leave unaddressed.

From a pharmacological standpoint, THC carries particular risks in older adults, including cognitive impairment, fall risk, orthostatic hypotension, and drug interactions with commonly prescribed medications such as anticoagulants, antihypertensives, and sedatives. The finding that older patients already receive less THC-dominant flower is reassuring but does not eliminate these concerns. Clinicians working with older adults interested in cannabinoid therapy should conduct a thorough medication interaction review before initiating any product, document baseline function using validated instruments, and schedule structured follow-up within the first month to assess both benefit and adverse effects before continuing treatment.

Study at a Glance

Study Type

Prospective observational patient registry (T21)

Population

4,228 adults prescribed cannabis-based medicinal products at UK private telemedicine clinics; 198 aged 65 and older

Intervention

Cannabis-based medicinal products (oils, flowers, various THC:CBD ratios) as prescribed in routine clinical care

Comparator

None (within-group pre-post comparison; age-stratified subgroup analysis)

Primary Outcomes

EQ-5D-5L (quality of life), EQ-5D-5L VAS (general health), PHQ-9 (mood/depression), Pittsburgh Sleep Quality Index items (sleep)

Sample Size

4,228 at baseline; 2,455 at 3-month follow-up (98 aged 65+)

Journal

Drugs & Aging

Year

2024

DOI or PMID

Not available from extracted text

Funding Source

Not specified in extracted text

What Kind of Evidence Is This

This is an original research article reporting prospective observational data from a multi-centre patient registry without randomization, blinding, or a control group. It sits in the lower tier of the evidence hierarchy for therapeutic questions. The single most important inference constraint is that any reported improvement in well-being cannot be causally attributed to cannabis-based medicinal products, because the design cannot distinguish treatment effects from placebo response, natural disease fluctuation, regression to the mean, or attrition-driven selection bias.

How This Fits With the Broader Literature

This study extends a small but growing body of observational research on cannabinoid use in older adults, including prior analyses of Israeli medical cannabis registries that similarly reported pain relief and improved function in geriatric populations but shared the same fundamental design limitations. It aligns with the consistent descriptive finding that older cannabis patients tend to be more cannabis-naive and to receive lower-potency products. What remains conspicuously absent from the broader literature is any randomized controlled trial of cannabis-based medicinal products specifically designed for and powered in adults over 65. Until such trials exist, descriptive registry data like these serve primarily to define the clinical landscape and generate testable hypotheses rather than to guide treatment decisions.

Common Misreadings

The most likely overinterpretation is reading the statistically significant improvements in quality of life, mood, and sleep as evidence that prescribed cannabis works for older adults. This exceeds what the data support. Without a control group, it is impossible to know whether patients would have improved to the same degree with placebo, with the passage of time, or simply through the structured clinical attention that registry participation entails. The 50% attrition rate in the older subgroup compounds this concern: if patients who did not improve were more likely to discontinue treatment and drop out of follow-up, the retained sample would show artificially favorable outcomes regardless of actual treatment effect.

Bottom Line

This registry study provides the most detailed UK portrait to date of older adults who seek prescribed cannabis, revealing a population that is predominantly female, pain-focused, cannabis-naive, and prescribed lower-THC formulations. The self-reported improvements in well-being are hypothesis-generating but cannot be attributed to treatment given the uncontrolled design and substantial attrition. Clinicians should use these data to inform patient counseling and clinical planning while recognizing that randomized controlled trials remain essential before efficacy claims in this population are warranted.

References

1. Sheridan B, et al. Cannabis-based medicinal products in older adults: patient characteristics, prescribing patterns, and self-reported well-being outcomes from the UK T21 registry. Drugs & Aging. 2024. [DOI not available from extracted text.]